Novo Nordisk: Priced For Disaster

Stone Fox CapitalInvesting Group LeaderFollow5ShareSavePlay(6min)CommentsSummaryNovo Nordisk shares have slumped despite a promising partnership with Hims & Hers Health to distribute semaglutide drugs via telehealth platform.The agreement grants HIMS access to FDA-approved Ozempic and Wegovy in multiple dosages, expanding patient reach and options.The Wegovy pill continues to enjoy strong prescription growth via first-mover advantage.The stock trades at only 11x '26 EPS targets and offers a 5% dividend yield, as NVO is priced for a lot of negative outcomes.Looking for more investing ideas like this one? Get them exclusively at Out Fox The Street. Learn More »Eduardo Monroy Husillos/iStock via Getty Images Despite a promising partnership with a leading online health platform, Novo Nordisk A/S (NVO) has only slumped to new lows. The biopharma already has promising oral GLP-1 sales, but the market just isn't happyThis article was written byStone Fox Capital55.25K FollowersFollowStone Fox Capital is an RIA from Oklahoma. Mark Holder is a CPA with degrees in Accounting and Finance. He is also Series 65 licensed and has 30 years of investing experience, including 15 years as a portfolio manager. Mark leads the investing group Out Fox The Street where he shares stock picks and deep research to help readers uncover potential multibaggers while managing portfolio risk via diversification. Features include various model portfolios, stock picks with identifiable catalysts, daily updates, real-time alerts, and access to community chat and direct chat with Mark for questions. Learn more.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in NVO over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.